Received Feb 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | Y357R | — |
on January 21, 2026 a patient inadvertently received a third dose of Shingrix.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 67-year-old female patient who received Herpes zoster (Shingrix) (batch number Y357R, expiry date 06-JUN-2027) for prophylaxis. Previously administered products included Shingrix (1st dose received on 2022) and Shingrix (2nd dose Received on 2022). On 21-JAN-2026, the patient received the 3rd dose of Shingrix. On 21-JAN-2026, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: on January 21, 2026 a patient inadvertently received a third dose of Shingrix.). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 04-FEB-2026 The patient had inadvertently received a third dose of Shingrix. The patient had already completed the standard Shingrix vaccination schedule in 2022. The reporter reported that the patient had not presented any immediate side effects. The reporter stated that the patient had not experienced any side effects after one week.